The Wages of Sin - a Small Illustration of How Executives Can Personally Profit from Bad Corporate Behavior in Health Care
Conclusions < /b > < br / > < br / > So this case appears to be a step forward, in that not all the people who apparently authorized, directed, or implemented the bad behavior could escape any negative consequences. & nbsp; Keep in mind, however, that no one above the two convicted executives, no one at Johnson and Johnson who decided to acquire Acclarent, and let it continue its previous activities, seemed to suffer any negative consequences. & nbsp; How much money those executives might have received in response to the revenues that the new subsidiary brought in is unknown. < br / > < br / > In conclusion, this case show...
Source: Health Care Renewal - July 27, 2016 Category: Health Management Tags: adulterated devices crime Ethicon impunity Johnson and Johnson legal settlements medical devices perverse incentives Source Type: blogs
The Rigid Patient
A 24-year-old man with a history of schizophrenia presented with altered mental status. His mother said he had become more catatonic and rigid over the previous two days. She reported that he was prescribed Abilify 5 mg by mouth daily for three years, but a long-acting depot of Abilify 400 mg had been administered two days before by court order. His vital signs include a heart rate of 120 bpm, blood pressure 140/90 mm Hg, temperature 38.5°C, respiratory rate is 14 bpm, and SPO2 is 98% on room air. The patient is alert and diaphoretic. Pupils are 3 mm. Cogwheeling, rigidity, and two beats of ankle clonus are also o...
Source: The Tox Cave - June 2, 2016 Category: Emergency Medicine Tags: Blog Posts Source Type: blogs
FDA Approves New Drug Vraylar
A new antipsychotic drug that can be used to treat schizophrenia and bipolar disorder in adults has been approved by the FDA. Vraylar belongs to a class of drugs known as atypical antipsychotics. Others in this group include Abilify (aripiprazole), Seroquel (quetiapine) and Risperdal (risperidone). (Source: Weird Cake: Myopic musings from a bipolar survivor)
Source: Weird Cake: Myopic musings from a bipolar survivor - September 29, 2015 Category: Psychiatry Source Type: blogs
Read it and weep - then get angry!
The Deadly Corruption of Clinical TrialsUpdate (4/3/2015): After nearly 11 years of obfuscation and denial surrounding the tragic death of Dan Markingson, the University of Minnesota has suspended enrollment in psychiatric drug trials. This comes in response to a blistering report issued by the Minnesota State Legislative Auditor that cites "serious ethical issues" and vindicates much of the reporting in the story below. Read more from Carl Elliott about the fallout from the report here.IT'S NOT EASY TO WORK UP a good feeling about the institution that destroyed your life, which may be why Mary Weiss i...
Source: PharmaGossip - April 4, 2015 Category: Pharmaceuticals Authors: insider Source Type: blogs
Read it and weep - then get angry!
The Deadly Corruption of Clinical TrialsUpdate (4/3/2015): After nearly 11 years of obfuscation and denial surrounding the tragic death of Dan Markingson, the University of Minnesota has suspended enrollment in psychiatric drug trials. This comes in response to a blistering report issued by the Minnesota State Legislative Auditor that cites "serious ethical issues" and vindicates much of the reporting in the story below. Read more from Carl Elliott about the fallout from the report here.IT'S NOT EASY TO WORK UP a good feeling about the institution that destroyed your life, which may be why Mary Weiss i...
Source: PharmaGossip - April 3, 2015 Category: Pharmaceuticals Authors: insider Source Type: blogs
Same Old, Same Old - Johnson and Johnson Settles Charges it Concealed Adverse Effects of Risperdal, Vaginal Mesh Device, Pleads Guilty to Selling Adulterated Tylenol, Announces CEO Got 48% Raise to $25 Million
We have devoted a lot of bytes over the years to the stream of allegations and ethical questions about Johnson and Johnson, the giant pharmaceutical/ biotechnology/ device company, and resulting legal actions. Meanwhile, the company has bestowed a gushing stream of money on its top executives. Its almost spring, 2015, and it seems nothing has changed.Johnson and Johnson's Latest Legal MisadventuresJury Verdict that Company Concealed Harms of Risperdal Let us start with the latest legal news about J&J. In late February, 2015, as reported on the PharmaLot blog by Ed Silverman,In a setback to Johnson &am...
Source: Health Care Renewal - March 18, 2015 Category: Health Management Tags: adulterated drugs adverse effects Alex Gorsky crime deception Johnson and Johnson legal settlements manufacturing problems William Weldon Source Type: blogs
Cases: Benign Prostatic Hypertrophy (BPH) as a hospice diagnosis?
Conclusion: In this case, a simple condition that is easily treatable in most men became one that we expected to lead to Mr. K’s death. However, the diagnosis that led it to become life-limiting was Mr. K’s dementia, and the heavy burden which BPH treatments would have placed on him. Mr. K’s daughter based her decision on Mr. K’s values, saying that if the father she was raised by was able to see himself in his current condition, he would have wanted both to stay in place and to be allowed to die with dignity. Forced catheterization and antipsychotic treatment might have prolonged his life by years but would have ...
Source: Pallimed: A Hospice and Palliative Medicine Blog - January 6, 2015 Category: Palliative Carer Workers Tags: cases childers emergency care hospice medications POLST urology Source Type: blogs
Should we use antipsychotics to treat ADHD?
Polypharmacy, or use of multiple psychiatric drugs, for treatment of attention deficit hyperactivity disorder (ADHD) is on the rise. A recent study compared treatment with basic therapy (stimulants plus parent training) with augmented therapy (those two plus risperidone, an atypical antipsychotic). The study concluded that treatment with risperidone was superior.
When children show dramatic improvements in behavior on risperidone, now being prescribed with increasing frequency for ADHD and a range of other disorders that represent difficulty with emotional regulation, we need to ask ourselves one question. Does this ch...
Source: Kevin, M.D. - Medical Weblog - October 19, 2014 Category: Journals (General) Authors: Claudia M. Gold, MD Tags: Conditions Pediatrics Psychiatry Source Type: blogs
Do I Turn to the Left Cheek or the Right Cheek?
Rebecca, my almost platinum mane elven nurse, couldn’t remember which cheek we injected the last time I took my Risperdal Consta. “Let’s try the right one,” she said as she also followed with, “Here goes a big prick!” We try to alternate between my butt cheeks to minimize scar tissue over time. Dad was waiting out in his car on me. He smiled warmly as I climbed back into the car with my next appointment card. He was eager to get that little card and stuck it in his shirt pocket. “As usual,” I told him. “Rebecca is like clockwork.” I got back in my car at my father’s former pharmacy and he...
Source: The 4th Avenue Blues - July 31, 2014 Category: Mental Illness Authors: Andrew Quixote Source Type: blogs
The Good Kind of Small Talk…
“How is your daughter?” I will perkily ask my nurse, Rebecca, in the morning as I take my place in the examining room. This immediately sets forth in motion the kind of small talk that is on a doable basis for me. I sit and smile as Rebecca regales me in tales of her young daughter who is on a big Lego kick at the moment. My main duty is to act as interested as possible and respond in an appropriate manner. I got on this tangent tonight because my father just called me and reminded me that my injection of Risperdal Consta in the ole derrière is tomorrow. This is my father’s so-called insurance that I wi...
Source: The 4th Avenue Blues - March 19, 2014 Category: Mental Illness Authors: Andrew Quixote Source Type: blogs
The Greedy Leading the Greedy - Multimillionaire Former Johnson and Johnson CEO Approved Huge Compensation for JP Morgan Chase CEO After Company Paid $20 Billion in Legal Settlements
JP Morgan Chase CEO Got Huge Raise Despite Company's Recent Huge Legal Settlements The current compensation set by the board of directors of JP Morgan Chase for CEO Jamie Dimon, $20 million a year, has attracted some attention (e.g., see this commentary by Matt Taibbi), especially given the contrast between his raise and the $20 billion or so the company had to pay out last year in settlements of allegations of unethical practices. A New York Times opinion piece rushed to Mr Dimon's defensein the world of executive compensation, especially when viewed from the rarefied perspective of other chief executives, and more...
Source: Health Care Renewal - January 31, 2014 Category: Health Medicine and Bioethics Commentators Tags: boards of directors executive compensation finance impunity Johnson and Johnson JPMorgan Chase legal settlements William Weldon Source Type: blogs
The Camel's Aching Back - Johnson and Johnson and Novartis Fined 16 Million Euro for "Anticompetitive" Scheme to Delay Generic Fentanyl
Legal and regulatory actions unfavorable for giant pharmaceutical, biotechnology and device company Johnson and Johnson just keep coming. We last discussed such a story only two weeks ago here. The Latest Case This latest story got only desultory US coverage from the wire services. The most complete version is in the European Commission press release. The basics were:The European Commission has imposed fines of € 10 798 000 on the US pharmaceutical company Johnson & Johnson (J&J) and € 5 493 000 on Novartis of Switzerland. In July 2005, their respective Dutch subsidiaries concluded an ...
Source: Health Care Renewal - December 17, 2013 Category: Health Medicine and Bioethics Commentators Tags: antitrust Fentanyl Johnson and Johnson mission-hostile management narcotics Netherlands Novartis restraint of competition Source Type: blogs
A New, and Huge ($2.2 Billion) Settlement for Johnson and Johnson, but "No Individuals were Charged with Wrongdoing"
The march of legal settlements made by big health care organizations has resumed with a bang. As reported in most major media outlets, giant drug/ device/ biotechnology company Johnson and Johnson has made a big settlement with the US Department of Justice.The Basics of the SettlementAs reported by Bloomberg / Businessweek, Johnson & Johnson agreed to resolve criminal and civil probes into the marketing of Risperdal, an antipsychotic drug, and other medicines by paying more than $2.2 billion, one of the largest U.S. health-fraud penalties. J&J’s Janssen unit will plead guilty to a misdemeanor criminal ...
Source: Health Care Renewal - November 5, 2013 Category: Health Medicine and Bioethics Commentators Tags: deception kickbacks Johnson and Johnson impunity crime marketing legal settlements Source Type: blogs
Impacts of Pharmaceutical Marketing and Healthcare Services in the District of Columbia: Focus on Antipsychotics in the Elderly
In April of last year, we wrote about Washington, DC's AccessRX Act, which requires pharmaceutical companies that market products in the District to file annual reports on marketing expenditures.
In 2011, 158 pharmaceutical companies reported spending a total of $83.7 million on marketing activities in DC, including $57.9 (69.2%) million on employee and contractor expenses, $18.9 (22.5%) million on gifts and payments, and $6.9 (8.2%) million on advertising. A 2009 report addressed pharmaceutical marketing and healthcare services more broadly in DC. Additional reports were then published in for 2010 and 2011.
Hos...
Source: Policy and Medicine - October 29, 2013 Category: Health Medicine and Bioethics Commentators Authors: Thomas Sullivan Source Type: blogs
